Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Detection of misfolded tau protein

A misfolding, protein technology, applied in the field of detection of misfolded TAU protein, can solve problems such as impracticality

Active Publication Date: 2020-03-06
安培里翁公司 +6
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In conclusion, RT-QuiC analysis is generally ineffective and impractical for 4R tauopathies including 4R predominant and 4R+3R mixed tauopathies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Detection of misfolded tau protein
  • Detection of misfolded tau protein
  • Detection of misfolded tau protein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0149] Example 1: Preparation of synthetic Aβ oligomers

[0150] Aβ1-42 was synthesized using solid-phase N-tert-butoxycarbonyl chemistry at the W. Keck facility at Yale University and purified by reverse-phase HPLC. The final product was lyophilized and characterized by amino acid analysis and mass spectrometry. To prepare stock solutions free of aggregated, misfolded Aβ protein, aggregates were dissolved at high pH and filtered through a 30 kDa cut-off filter to remove residual aggregates. To prepare different types of aggregates, seedless Aβ1-42 (10 μM) solutions were incubated at 25° C., 0.1 M Tris-HCL, pH 7.4 for different times under agitation. The preparations included A[beta] monomers and mixtures of fibrils, protofibrils and soluble misfolded A[beta] protein in different ratios depending on the incubation time. The degree of aggregation was characterized by ThT fluorescence emission, electron microscopy after negative staining, dot blot studies with A11 conformation...

Embodiment 2

[0153] Example 2: Detection of synthetic Aβ oligomers by Aβ-PMCA

[0154] Example 2A. Seeding of Aβ aggregation by using or not using different amounts of synthetic soluble misfolded Aβ protein (control (no Aβ oligomers); or 3 of synthetic soluble misfolded Aβ protein in the presence of Thioflavin T 80, 300, and 8400 femtomoles) were incubated with seed-free Aβ1-42 solutions for study. Aβ-PMCA general procedure: 2 μM aggregate-free Aβ1-42 solution in 0.1M Tris-HCL pH7.4 (total volume 200 μL) was placed in an opaque 96-well plate and incubated alone or after synthetic Aβ aggregates ( Prepared by incubating for 5 h as described in Example 1) or in the presence of a 40 μL aliquot of CSF. Samples were incubated in the presence of 5 μM Thioflavin T (ThT) at a constant temperature of 22°C with cyclic agitation using an Eppendorf thermomixer (1 min at 500 RPM followed by 29 min without shaking). At various time points, ThT fluorescence was measured in 485 nm plates after excitation...

Embodiment 2B

[0155] Example 2B: Using an amplification cycle that combines stages of incubation and physical disruption. Figure 2AThe samples in were incubated under circulating agitation (stirring at 500 RPM for 1 minute, then 29 minutes without shaking). Aggregation was measured over time by the binding of Thioflavin T (ThT) to amyloid fibrils using a flat plate spectrofluorometer (excitation: 435; emission: 485 nm). Graphs show mean and standard error of 3 replicates. The concentration of Aβ oligomers was estimated assuming an average molecular weight of 170 kDa. Figure 2B is a graph showing cycle-accelerated amplified amyloid formation measured by ThT fluorescence as a function of time seeded with various concentrations of the synthetic soluble oligomeric Aβ protein of Example 1. FIG. Under these conditions, the aggregation of monomeric Aβ1-42 protein induced with 8400, 300, 80 and 3 fmol of synthetic soluble misfolded Aβ protein was faster and easier to distinguish from the aggreg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods and kits are provided for amplifying and detecting misfolded tau protein from samples, for example, from patients having tauopathies such as Alzheimer's Disease, Progressive Supranuclear Palsy, and the like.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 507,166, filed May 16, 2017, the entire contents of which are hereby incorporated by reference. Background technique [0003] Tauopathies may include, for example, Alzheimer's disease (AD), Parkinson's disease (PD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), corticobasal degeneration (CBD), Mild cognitive impairment (MCI), argyrophilia (AgD), traumatic brain injury (TBI), chronic traumatic brain injury (CTE) and dementia pugilistica (DP), etc. Misfolded tau aggregates and fibrils can form and accumulate through nucleation and growth. Misfolded tau aggregates may cause cellular dysfunction and tissue damage, among other effects. [0004] Real-time shock-induced transformation (RT-QuiC) has been shown to induce replication of the 3-repeat (3R) tau isoform in brain homogenate and cerebrospinal fluid samples drawn from ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/48G01N33/50G01N33/68
CPCG01N2800/2821G01N33/6896G01N2333/4709G01N2333/47
Inventor 克劳迪奥·索托-贾拉罗素·M·莱博维兹贝内迪克特·K·沃尔拉特穆罕默德·沙纳瓦兹尼古拉斯·门德斯·迪纳马卡
Owner 安培里翁公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com